Expanded Alternatives of CRISPR-Cas9 Applications in Immunotherapy of Colorectal Cancer.

ABSTRACT: Immunotherapy for colorectal cancer (CRC) is limited to patients with advanced disease who have already undergone first-line chemotherapy and whose tumors exhibit microsatellite instability. Novel technical strategies are required to enhance therapeutic options and achieve a more robust immunological response. Therefore, exploring gene analysis and manipulation at the molecular level can further accelerate the development of advanced technologies to address these challenges. The emergence of advanced genome editing technology, particularly of clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 9, holds promise in expanding the boundaries of cancer immunotherapy. In this manuscript, we provide a comprehensive review of the applications and per

SUBMITTER: Arroyo-Olarte R 

PROVIDER: S-EPMC10786962 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature